Buscomed

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buscomed

Property Description
Active ingredient Hyoscine Butylbromide
Pharmacological class Antispasmodic Agent
Primary Forms Tablets and Injectable Solution
Origin/Type Semisynthetic Derivative
General Purpose Relief of visceral spasm and associated pain

What Type of Medicine is Buscomed (Hyoscine Butylbromide)?

Buscomed is a registered brand name for a pharmaceutical preparation primarily classified as an Antispasmodic agent, intended for the targeted relaxation of smooth muscle tissue within the body's internal organs. Its active compound is Hyoscine Butylbromide (the International Nonproprietary Name, or INN), which places it pharmacologically within the Parasympatholytic group of medicines. Hyoscine butylbromide is utilized in the management of smooth muscle spasms, particularly in acute pain situations. This mechanism is intended to address the underlying muscle contraction causing discomfort. Buscomed is a semisynthetic derivative of the naturally occurring alkaloid scopolamine, chemically engineered to focus its effects on the periphery, minimizing the potential for effects on the central nervous system.


Composition and Available Forms of Buscomed

The medicine is a single-ingredient product whose active part, Hyoscine Butylbromide, is chemically identified as a Quaternary Ammonium Compound, a structural feature relevant to its limited systemic absorption and peripheral action. This relates to the drug's specialized, localized function within the digestive and urinary tracts. Buscomed is typically supplied as film-coated tablets for oral ingestion, which is the most common form for managing episodic pain, and as a sterile injectable solution provided in ampoules for parenteral use. This dual availability allows selection of the appropriate route of administration based on the urgency of the need for spasm relief.


What is the General Purpose of an Antispasmodic?

The general therapeutic purpose of Buscomed is to provide relief from discomfort and pain that arises from visceral spasm—the uncontrolled, painful tightening of the smooth muscles lining organs like the stomach, intestines, and bile ducts. A typical application involves managing the acute, cramping discomfort associated with passing kidney stones or intestinal dysfunction. This relief is achieved through the fundamental mechanism of smooth muscle relaxation, as the drug acts to interrupt the nerve signals that stimulate these involuntary contractions. The overall function of this medicine is the targeted resolution of the underlying cramp, addressing the source of the spasmodic discomfort rather than general pain suppression.

What side effects are possible with Buscomed?

Possible Side Effects and Safety Information

The regulatory profile for Buscomed (Hyoscine Butylbromide) establishes a clear spectrum of possible adverse reactions, classified by frequency as documented by official governmental health authorities.

Adverse reactions classified as Common (affecting 1 to 10 users in 100) are typically linked to the medicine's antispasmodic properties. These include dry mouth (Gastrointestinal disorders), tachycardia (increased heart rate, Cardiac disorders), dyshidrosis (abnormal sweating, Skin disorders), and accommodation disorders (difficulty focusing the eye, Nervous system disorders).

Less frequent effects are classified as Uncommon, such as various skin reactions (pruritus, urticaria, rash). A Rare effect documented is urinary retention (Renal and urinary disorders).

Serious adverse events are classified as Very Rare and pertain to Immune system disorders. These clinically significant reactions include anaphylactic shock, severe anaphylactoid reactions, and angioedema (swelling of the face or throat). Regulatory documents note that the injection (parenteral) route of administration carries an elevated potential for these severe reactions.

Safety Constraints and Special Considerations

Official labeling defines strict limitations (Contraindications) when the medicine must not be used. These include diagnosed conditions such as narrow-angle glaucoma, myasthenia gravis, megacolon, and intestinal obstruction (e.g., paralytic ileus). Additionally, a specific safety consideration is noted for patients with prostatic hypertrophy due to the officially documented increased potential for urinary retention.

Overdose and Emergency Response

Official Manifestations of Overdose

Overdose with Hyoscine Butylbromide (Buscomed) is formally documented in regulatory sources by a profile of pronounced anticholinergic symptoms. These manifestations include tachycardia (fast heart rate), dry mouth, urinary retention, reddening of the skin, and inhibition of gastrointestinal motility. Other documented signs are transient visual disturbances (accommodation disorders) and drowsiness. The most severe event noted in regulatory reports is Cheynes-Stokes respiration, though official labeling often includes the statement that serious signs of poisoning have not been observed in humans following acute overdosage.

When Urgent Medical Help Is Required

Regulators mandate that immediate medical attention must be sought upon the suspicion or recognition of any signs of overdose. Emergency services should consider intubation and artificial respiration if respiratory paralysis develops.

The official management protocols described in the labeling detail that symptoms are documented to respond to parasympathomimetics. Supportive measures include specific steps for oral overdosage (e.g., gastric lavage with medicinal charcoal) and managing specific symptoms, such as the requirement for catheterisation if urinary retention is present. Specific patient needs, such as those with glaucoma, require the local administration of pilocarpine as an immediate intervention.

Therapeutic Uses of Buscomed

What Buscomed Treats: Main Uses and Benefits

Buscomed (Hyoscine Butylbromide) is a medication generally used to provide symptomatic relief in conditions where symptoms are related to physical discomfort, relevant in contexts marked by increased discomfort or tension. It is commonly used to help with painful stomach cramps, including those linked with Irritable Bowel Syndrome (IBS).

It is applied in clinical settings that involve acute or unstable symptom patterns, such as sudden, severe spasms in the gastrointestinal or genitourinary tracts. This includes managing intense symptoms of biliary colic or renal colic, where symptoms related to increased muscular activity create noticeable physiological strain. The medication is relevant for easing symptoms related to functional disorders, such as painful flare-ups of IBS and spasms associated with diverticular disease, as well as managing episodic manifestations like symptomatic dysmenorrhea (painful menstrual cramps). This supportive relief, offered when symptoms interfere with routine activities, may assist with maintaining functional stability during periods of heightened symptoms.


“This medication is used in situations involving certain distressing symptoms, supporting the patient during difficult episodes by easing distress.”


Quick Fact: Relief for Acute Visceral Cramping


Eligibility and Restrictions for Use

Who Can and Cannot Use Buscomed?

Eligibility for Buscomed (Hyoscine Butylbromide) is strictly defined by regulatory documents that outline official population restrictions and absolute contraindications. The medicine is generally approved for use in adults and adolescents.


Contraindicated Populations (Absolute Ban)

The medicine is contraindicated and must not be used in patients with certain pre-existing conditions. These absolute exclusions include:

  • Myasthenia Gravis or Megacolon.
  • Obstructive Ileus or Mechanical Stenosis of the gastrointestinal tract.
  • Untreated Narrow-Angle Glaucoma.
  • Obstructive Prostatic Hypertrophy leading to urinary retention.
  • Tachycardia, Angina, or Cardiac Failure (for the injectable form only).

Age and Special Population Restrictions

Age-Related Eligibility: The oral film-coated tablets are not recommended for children under 6 years of age.

Physiological Status: Use during pregnancy and breastfeeding is officially not recommended due to insufficient human safety data in the labeling.

Conditional Restrictions: Patients taking anticoagulant drugs are restricted from receiving the medicine via the intramuscular injection route.

What should I know about interactions with other medicines?

The official regulatory profile for Buscomed (Hyoscine Butylbromide) documents interactions that are primarily pharmacodynamic, leading to additive effects, or pharmacokinetic, resulting from altered absorption.

Contraindicated Combinations

Classification Restriction Regulatory Basis
Route-Specific Prohibition Intramuscular (IM) injection is prohibited in patients receiving anticoagulant drugs due to the documented risk of intramuscular haematoma formation. Subcutaneous or intravenous routes may be used in these cases.

Pharmacodynamic Interactions

Co-administration with other medicines can intensify or counteract the effects of Buscomed:

  • Intensification: The anticholinergic effect may be intensified by other anticholinergic agents, including tri- and tetracyclic antidepressants, antihistamines, quinidine, and amantadine. This includes other anticholinergics like ipratropium and tiotropium. The tachycardic effects of beta-adrenergic agents may also be enhanced.
  • Diminution: Concomitant treatment with dopamine antagonists (e.g., metoclopramide) may result in a diminution of effects on gastrointestinal motility due to antagonistic actions.

Exposure and Timing Restrictions

  • Reduced Absorption: Antacids or adsorbent antidiarrheals may reduce the overall absorption of Buscomed. To mitigate this effect, the regulatory requirement is that Buscomed should be given at least one hour before these medicines.
  • Substance Restriction: Consumption of alcohol is advised against while using this medicine.

Regulatory documents establish the interaction structure by identifying combinations that must be absolutely avoided under certain conditions, substances that require mandatory timing separation, and drug classes that carry an officially documented risk of additive effects.

Mechanism of Action

Targeting the Peripheral Autonomic Nervous System

The core mechanism involves the drug's action as a parasympatholytic agent, primarily targeting the muscarinic acetylcholine receptors located on the walls of internal organs. The unique chemical structure of the drug ensures this competitive antagonism is focused exclusively on the periphery, interrupting the cholinergic nerve signals that command the involuntary contraction of smooth muscle tissue.

Decoupling Muscle Contraction from Nerve Signals

By blocking the muscarinic receptors, the drug actively suppresses the molecular cascade that triggers muscle fiber shortening. This inhibition prevents the necessary release of intracellular calcium ( Ca^2+), which is the final common signal for contraction. This physiological adjustment leads directly to the relaxation of hyperactive smooth muscle, which modifies the state of visceral smooth muscle motility.

Mechanism-Specific Limitations

The functional scope of the mechanism is strictly confined to the smooth muscle relaxation resulting from the blockade of cholinergic input. This mechanistic specificity means the drug does not interact with molecular pathways associated with general nociception (pain signaling) and is physiologically constrained when addressing functional changes originating from sources other than cholinergic-mediated smooth muscle contraction.

Dosage and Administration Information

Instruction Map: How to use Buscomed (Hyoscine Butylbromide) — General Administration Guidelines

This map consolidates the instructions for use, detailing the administration rules.


Administration Scope

Parameter Instruction
Route of administration: Oral (Tablets), Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC) (Injectable Solution).
Dosing schedule (Adults 12 yrs): Oral: 10 mg to 20 mg up to four times daily. Parenteral: 20 mg to 40 mg per administration. Maximum Parenteral Daily Dose: 100 mg.
Timing in relation to meals: Tablets may be taken with or without food.
Preparation requirements: Injectable solution may be used undiluted or diluted with standard solutions (e.g., 0.9% Sodium Chloride) to aid in slow IV administration.
Age-group administration rules: Oral (6–11 yrs): 10 mg up to three times daily. Oral (< 6 yrs): Not recommended. Parenteral (Children): Max 1.2 mg/kg daily.
Missed-dose rules: If a dose is missed, it should be skipped, and the regular dosing schedule should be resumed; do not take a double dose.
Special procedural conditions: Oral tablets must be swallowed whole (do not crush or chew). IV injection must be administered slowly. IM injection should be avoided if the patient is on anticoagulant therapy.

Instruction Classifications (High-Level)

Classification Specification
Administration method type: Oral (episodic use) and Parenteral (IV/IM/SC for acute use or diagnostic procedures).
Frequency pattern: Multiple times per day (up to four or five times daily, or repeated after 30 minutes for parenteral).
Use-context constraints: Short-term use only; should not be taken on a continuous daily basis or for extended periods without medical investigation.

Resulting Procedural Structure

Step sequence:

  • Select Route: Choose between the oral tablet or parenteral injection based on the required speed and severity of the condition.
  • Administer Dose: Deliver the specific, age-appropriate milligram amount within the designated range, adhering to preparation and intake instructions.
  • Observe Frequency: Repeat the dose only within the designated time intervals, not exceeding the maximum daily dose established in the labeling.
  • Limit Duration: Discontinue use once the acute episode has passed, as continuous, daily use is not permitted without a physician’s review.

Connection to the overall use protocol (2–4 sentences): The instructions define the structured process for administering this medicine, detailing the forms, permissible routes, and non-exceedable dose limits. These rules limit use to standard ranges and repetition schedules, ensuring the medication is delivered as intended.

Recent Clinical Evidence

The clinical evaluation of Buscomed (Hyoscine Butylbromide) focuses on research detailing the structure and scope of studies into its use for muscle spasms in the digestive and genito-urinary tracts. The evidence base adheres to findings reported in authoritative governmental and peer-reviewed scientific sources.

Evidence for Use in General Abdominal Cramping

The evidence base for acute gastrointestinal cramping includes multiple Randomized Controlled Trials (RCTs) and comparisons against placebo. These short-term studies examined patient-reported outcomes describing perceived discomfort. Research describes patterns of symptom change in participants with cramp-related abdominal pain. Comparative trials also examined outcomes reported by patients when compared against other non-opioid pain relievers. However, the evidence structure is mainly based on short-term observations, and limited insight exists into implications of use over extended periods.

Evidence for Use in Irritable Bowel Syndrome (IBS)

The medicine was studied for symptoms related to IBS, a condition characterized by fluctuating manifestations. Analyses aggregating data from multiple trials reported that a greater proportion of participants noted change in overall IBS symptoms and abdominal pain. The evidence level is frequently characterized as moderate due to heterogeneity in the data, as some systematic reviews described mixed findings regarding consistency, often linked to modest sample sizes in the original trials.

Evidence in Acute Spasmodic Conditions and Special Populations

Research was evaluated in acute settings for conditions such as renal colic and dysmenorrhea (painful menstrual cramps). Studies examined changes in pain intensity. The overall role of the medicine when used alone for acute spasmodic episodes in acute care settings is not fully established by the existing controlled evidence. Additionally, studies examined this medicine in children and adolescents (aged 6 and older), but data for certain age groups remain insufficient, with limited dedicated RCTs exploring outcomes in the pediatric population.

Frequently Asked Questions (FAQ)

Common questions about Buscomed (FAQ)

Q: Is Buscomed a type of pain reliever?

Official documents describe the medicine's primary function as relieving pain that results from smooth muscle spasm (cramping). Its mechanism works by relaxing the cramped muscle tissue in organs like the gut. Regulatory information indicates the medicine is not described as addressing general pain signals (nociception), which are the targets of common analgesics.

Q: What is the difference between Buscomed and another common stomach medicine (e.g., Pepto-Bismol)?

Regulatory documents classify Buscomed as an antispasmodic agent, which means it specifically targets and relaxes the painful muscle contractions in the gut. Other common stomach medicines, like antacids or bismuth-based preparations, work using different mechanisms, such as neutralizing stomach acid or coating the digestive tract. The functional difference lies in their mechanism: antispasmodics target muscle spasms, while other classes target acid or irritation.

Q: Are there dietary restrictions while taking Buscomed?

Official product labeling specifically advises against the consumption of alcohol while using this medicine. No other specific food or general dietary restrictions are explicitly documented in regulatory materials.

Q: Can older adults safely use Buscomed?

Official labeling highlights that the use of this medicine is restricted by certain pre-existing conditions that are considered specific safety concerns for all adults, including older populations. Due to its mechanism of action, conditions such as untreated narrow-angle glaucoma or prostatic hypertrophy are listed as critical safety contraindications.

Q: Can Buscomed be taken with cold or flu medicine?

Regulatory documents list certain drug classes, such as antihistamines (often found in cold medicines) and some antidepressants, that may increase the effect of Buscomed. Patients who use cold or flu medicines that contain these specific documented classes of substances should be aware of the potential for intensified effects, according to regulatory information.

Q: Are there any long-term side effects associated with Buscomed use?

Official labeling specifies the medicine is intended for short-term use only and is not recommended for continuous daily use over extended periods. Due to this constraint, regulatory data is limited regarding the implications or specific adverse effects that might result from long-term, continuous use.

Q: Does Buscomed affect blood pressure?

Official documents list tachycardia (an increased heart rate) as a common adverse reaction related to the medicine's antispasmodic properties. Changes to blood pressure are not explicitly documented as a common, uncommon, or rare side effect in the regulatory profiles.

Q: Does Buscomed treat the cause of spasms or just the symptoms?

The medicine is described as acting on the exact mechanism that directly causes the cramp—the specific nerve signals triggering muscle contraction. However, the regulatory description of the mechanism indicates it does not address the underlying disease or chronic condition that may be initiating the spasm.

Q: Is there a liquid or chewable form of Buscomed?

Regulatory documents specify that the medicine is supplied in two primary forms: film-coated tablets for oral use and a sterile injectable solution for use by a healthcare professional. No other forms, such as liquid or chewable tablets, are listed in the official product information.

Q: Why does Buscomed need to be swallowed whole (if applicable)?

The official product labeling states that the tablets are a coated form and are required to be swallowed whole (not crushed or chewed) as a procedural constraint. This rule is typically put in place to ensure the protective film coating remains intact until the medicine reaches the correct part of the digestive tract for proper absorption.

Q: Are there different strengths of Buscomed tablets available?

Regulatory information indicates the medicine is used in 10 mg to 20 mg increments. The medicine is frequently supplied in 10 mg tablet strengths in regulated markets.

Q: Why is Buscomed not recommended for people with heart issues?

Regulatory labeling contraindicates the injectable solution for patients who have specific heart conditions, including tachycardia (rapid heart rate) or cardiac failure. This restriction is due to the medicine's mechanism of action on the autonomic nervous system, which can potentially cause an increase in heart rate.

Q: Is dizziness a common side effect of Buscomed?

A review of the official documentation indicates that dizziness is not listed as a common, uncommon, or rare side effect of the medicine. The most common side effects are typically restricted to dry mouth, vision changes, and increased heart rate.

Q: Does Buscomed cause drowsiness?

Official regulatory documents do not list drowsiness as a documented common, uncommon, or rare side effect. This is consistent with the medicine's structure being designed to minimize effects on the central nervous system (CNS).

Q: Is it safe to drive or operate machinery after taking Buscomed?

The official regulatory label contains a warning that users should exercise caution when driving or operating machinery if they experience certain side effects. This caution is specifically advised if side effects like accommodation disorders (difficulty focusing the eye) or other vision issues are experienced.

Q: What are the signs of taking too much Buscomed?

Official documentation describes signs of potential overexposure or overdose, which are an intensification of the known anticholinergic effects, such as urinary retention or severe tachycardia. This information is intended for healthcare providers.

Q: Is it normal for Buscomed to change the color of urine or stool?

Official regulatory documents do not document or list any change in the color of urine or stool as a documented common, uncommon, or rare side effect.

Q: Can Buscomed make constipation worse?

Although the medicine works by reducing muscle movement (motility), constipation is not listed as a commonly reported adverse effect in the official regulatory documentation. The specific side effect of urinary retention (difficulty passing water) is noted as a rare occurrence.

Q: Is Buscomed habit-forming or addictive?

Official regulatory materials do not identify Buscomed as a controlled substance. Furthermore, the official labeling contains no warnings or documentation regarding a potential for abuse or dependence.

Q: Can Buscomed interfere with lab tests?

Official labeling does not typically list interference with routine laboratory tests. Regulatory information on interactions does not generally include this type of interference. However, it is important to confirm with a healthcare provider regarding any specific diagnostic procedure.

Q: Does Buscomed affect fertility?

While non-clinical animal studies have not shown evidence of adverse reproductive effects, official regulatory documents state that there are no adequate human data available on the medicine’s effect on fertility.

Q: Does Buscomed interact with birth control pills?

A review of official regulatory documents does not list a specific interaction between Buscomed and oral contraceptives (birth control pills).

Q: Does Buscomed contain lactose or gluten?

The complete list of inactive ingredients (excipients) for the tablets is contained in the regulatory labeling. This list specifies the inclusion of any known allergens, such as lactose (if present) or gluten.

How should Buscomed be stored and disposed of?

Official Storage Conditions

Formulation Required Temperature Environmental Protection
Oral Tablets Store below 25 C or 30 C (depending on region) Must be protected from light and stored in a dry place.
Injectable Solution Store below 30 C (86 F) Store in the outer carton to protect from light.

All forms must be kept out of the sight and reach of children, as mandated by regulatory labeling. Tablets should be maintained in their original blister pack. The injectable solution is strictly for single use only, and any unused solution remaining in an opened ampoule must be immediately discarded.

Disposal Requirements

Unused or expired Buscomed must be disposed of in accordance with local requirements. The official guidance states that medicines should not be thrown away via household waste or wastewater (sinks or toilets). The preferred method is to return expired or unwanted product to a pharmacist or a recognized drug take-back program for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buscomed found in:

A-Z Index: